

Aspochalamins A~D and Aspochalasin Z Produced by the Endosymbiotic

Fungus *Aspergillus niveus* LU 9575

II. Structure Elucidation

ALEXANDRA HÖLTZEL^a, DIETMAR G. SCHMID^a, GRAEME J. NICHOLSON^a, PHILIPP KRASTEL^b, AXEL ZEECK^b,
KLAUS GEBHARDT^c, HANS-PETER FIEDLER^c and GÜNTHER JUNG^{a,*}

^aInstitut für Organische Chemie, Universität Tübingen,
Auf der Morgenstelle 18, D-72076 Tübingen, Germany

^bInstitut für Organische Chemie, Universität Göttingen,
Tammannstr. 2, D-37077 Göttingen, Germany

^cMikrobiologisches Institut, Universität Tübingen,
Auf der Morgenstelle 28, D-72076 Tübingen, Germany

(Received for publication June 2, 2004)

The structures of new cytochalasan fungal metabolites aspochalamins A~D have been elucidated by ESI-FTICR-MS, NMR spectroscopy, and chiral amino acid analysis. Aspochalamins A~D consist of different aspochalasin skeletons connected at position C-19 to the *N* terminus of the tripeptidic moiety amide anthranoyl-L-alanine-*E*-dihydrotryptamide. Furthermore, the structure of a new aspochalasin analog, aspochalasin Z, was derived from its molecular mass and NMR data as 10-isopropyl-14-methyl[11]-cytochalasa-6Z,13*E*,19*E*-triene-1,21-dione.

Five novel metabolites with retention times of 7.5 (**1**), 11.6 (**2**), 12.2 (**3**), 12.8 (**4**), and 13.8 (**5**) minutes in the HPLC-DAD screening¹⁾ were isolated from the mycelium extract of the endosymbiotic fungus *Aspergillus niveus* LU 9575. The taxonomy of the producing organism, fermentation, isolation, and biological activities of the metabolites are described in the preceding paper²⁾. Here, we present the structure elucidation of these compounds.

Results

With respect to its retention time, UV-Vis spectrum, and isolation characteristics compound **1** which had been isolated along with aspochalasin D differed clearly from metabolites **2**~**5**²⁾. An ESI-mass spectrum provided a molecular mass of 369 Da for **1** (m/z [M+H]⁺ 370). The ¹H and ¹³C NMR data (Table 1) accounted for the presence of five methyl, five methylene, five *sp*³ methine and four *sp*²

methine groups, as well as one *sp*³ and four *sp*² quaternary carbons including two carbonyl carbons. A broad signal at δ_{H} 7.95 observed in the ¹H NMR spectrum was attributed to an amide group. Thus the molecular formula of **1** was deduced from its molecular mass and ¹H and ¹³C NMR data as C₂₄H₃₅NO₂. Analysis of ¹H-¹H-COSY, HSQC, and HMBC spectra established **1** as 10-isopropyl-14-methyl[11]-cytochalasa-6Z,13*E*,19*E*-triene-1,21-dione³⁾, a new member of the aspochalasin family designated as aspochalasin Z (Fig. 1). The (13*E*, 19*E*) configuration of the double bonds was concluded from the upfield chemical shift of C-25 (δ_{C} 16.7) and from the large vicinal coupling constant of ³*J*_{19,20}=16 Hz, respectively. Contrary to all known members of the aspochalasin family^{4~11)}, **1** lacks oxygen functionalities at positions C-17 to C-20 and can therefore be considered as the simplest aspochalasin analog discovered so far.

Metabolites **2**~**5** were analysed by high-resolution ESI-FTICR-MS, and molecular masses of 749 Da (**2**, **3**), 733 Da

* Corresponding author: guenther.jung@uni-tuebingen.de

Table 1. ^1H and ^{13}C NMR data for aspochalasin Z (1) and aspochalamins A~D (2~5).

	1 ^{a)}		2 ^{a)}		3 ^{a)}		4 ^{b,c)}		5 ^{b)}	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}
1	173.3 s	-	174.5 s	-	174.5 s	-	175.4 s	-	174.4 s	-
2	-	7.95	-	8.12	-	8.14	-	*	-	*
3	50.2 d	3.00	50.0 d	3.03	49.8 d	3.08	50.2 d	3.05	49.5 d	3.08
4	48.1 d	2.90	52.8 d	2.25	53.9 d	2.25	53.9 d	2.26	51.7 d	2.55
5	34.5 d	2.33	35.0 d	2.46	34.8 d	2.51	34.4 d	2.56	34.2 d	2.56
6	140.0 s	-	138.8 s	-	138.7 s	-	137.9 s	-	138.4 s	-
7	125.6 d ^{b)}	5.31	125.3 d	5.37	125.4 d	5.35	125.2 d	5.40	125.2 d	5.38
8	42.6 d	2.73	42.5 d	3.26	42.3 d	3.33	41.7 d	3.44	42.6 d	3.10
9	67.9 s	-	67.7 s	-	68.0 s	-	67.6 s	-	64.8 s	-
10	48.6 t	1.07	48.7 t	0.95	48.9 t	1.01	47.8 t	0.94	47.3 t	1.01
				1.01						1.09
11	13.3 q	1.16	12.9 q	1.12	12.9 q	1.15	12.4 q	1.09	12.4 q	1.14
12	19.6 q	1.71	19.4 q	1.71	19.4 q	1.72	18.9 q	1.68	18.7 q	1.68
13	125.4 d ^{b)}	5.97	124.3 d	6.08	125.5 d	6.19	124.2 d	6.12	122.5 d	6.35
14	136.6 s	-	136.0 s	-	135.9 s	-	137.1 s	-	135.2 s	-
15	40.7 t	1.90	36.7 t	1.99	32.7 t	1.83	39.5 t	2.05	40.9 t	2.03
				2.02		2.43		2.13		2.09
16	27.9 t	1.38	29.6 t	1.42	28.4 t	1.46	20.1 t	1.34	22.1 t	1.12
						1.56		1.51		1.59
17	27.1 t	1.50	78.5 d	3.75	70.9 d	3.50	34.2 t	1.69	19.0 t	1.23
		1.70						1.96		1.51
18	31.2 t	2.00	74.5 d	4.59	71.9 d	4.44	68.5 d	4.93	29.0 t	1.04
		2.05								1.72
19	141.8 d	6.59 ^{d)}	51.3 d	3.35	51.1 d	3.38	51.5 d	3.49	45.8 d	4.10
20	130.5 d	7.22 ^{d)}	42.7 t	1.93	43.0 t	1.91	41.5 t	2.09	41.6 t	2.24
				3.72		3.49		3.38		4.12
21	196.9 s	-	211.2 s	-	214.7 s	-	*	-	210.7	-
22	24.0 d	1.58	23.8 d	1.52	23.6 d	1.56	23.8 t	1.26	23.9 t	1.35
23 ^{e)}	23.6 q	0.79	23.2 q	0.72	23.2 q	0.77	22.4 q	0.65	22.4 q	0.74
24 ^{e)}	21.5 q	0.81	21.5 q	0.74	21.6 q	0.80	20.3 q	0.67	20.4 q	0.76
25	16.7 q	1.24	15.9 q	1.52	15.1 q	1.54	15.3 q	1.58	14.3 q	1.49

Table 1. (Continued).

	1 ^{a)}		2 ^{a)}		3 ^{a)}		4 ^{b,c)}		5 ^{b)}	
	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H
26			-	7.74	-	8.24	-	7.88	-	7.61
27			148.7 s	-	147.6 s	-	147.2 s	-	147.8 s	-
28			115.2 s	-	114.8 s	-	*	-	112.2 s	-
29			128.9 d	7.65	129.1 d	7.72	127.1 d	7.37	126.6 d	7.21
30			113.9 d	6.57	113.7 d	6.58	114.0 d	6.56	113.5 d	6.43
31			132.0 d	7.27	132.5 d	7.32	132.5 d	7.34	132.2 d	7.17
32			111.9 d	7.04	110.8 d	7.08	111.6 d	7.09	110.9 d	6.58
33			168.8 s	-	168.5 s	-	168.3 s	-	168.5 s	-
34			-	8.26	-	8.27	-	6.85	-	6.44
35			48.8 d	4.48	48.6 d	4.46	47.7 d	4.75	47.8 d	4.63
36			170.0 s	-	169.9 s	-	168.2 s	-	168.1 s	-
37			-	9.98	-	9.99	-	8.95	-	8.39
38 ^{f)}			119.8 d	7.27	120.0 d	7.27	*	7.33	119.1 d	7.40
39 ^{f)}			106.2 d	6.42	105.9 d	6.42	106.1 d	6.20	106.2 d	6.38
40			111.6 s	-	111.5 s	-	*	-	112.2 s	-
41			123.1 d	7.40	123.0 d	7.40	*	*	121.1 d	7.17
42			-	11.06	-	11.06	-	8.32	-	8.08
43			136.7 s	-	136.6 s	-	135.3 s	-	135.6 s	-
44			111.7 d	7.37	111.6 d	7.37	110.4 d	7.26	110.3 d	7.29
45			121.3 d	7.11	121.3 d	7.11	121.3 d	7.09	121.2 d	7.14
46			119.1 d	7.05	119.0 d	7.05	119.1 d	7.03	119.1 d	7.10
47			118.8 d	7.62	118.7 d	7.62	118.8 d	7.63	119.0 s	7.77
48			124.9 s	-	124.8 s	-	124.1 s	-	124.5 s	-
49			17.7 q	1.38	17.4 q	1.38	17.4 q	1.49	16.7 q	1.42


a) In DMSO-*d*₆. b) In CDCl₃. c) Compound **4** was unstable under the experimental conditions so that a complete assignment was not available. d) $^3J_{19,20} = 16$ Hz observed for **1**. e) Assignment of prochiral methyl groups is interchangeable. f) $^3J_{38,39} = 15$ Hz observed for **2-5**. g) Signals may be interchangeable. *) Signal not observed or assignment not possible.

(**4**), and 717 Da (**5**) were determined. It was evident from the measurement that metabolites **2** and **3** were isomers sharing the same molecular formula, and that the mass difference between metabolites **2/3** and **4**, and between **4** and **5** corresponded to the loss of one oxygen. A mixture of compounds **2~5** containing an internal standard was used to determine the molecular formulae. Using restraints derived from ^1H and ^{13}C NMR data molecular formulae of C₄₄H₅₅N₅O₆ (**2/3** m/z [M+H]⁺ 750.42475 found, 750.42251 calcd.), C₄₄H₅₅N₅O₅, (**4**, m/z [M+H]⁺ 734.43087 found,

734.42759 calcd.), and C₄₄H₅₅N₅O₄ (**5**, m/z [M+H]⁺ 718.43302 found, 718.43268 calcd.) were established.

^1H and ^{13}C NMR data of **2** (Table 1) comprised signals for six methyl, four methylene, nine sp^3 and thirteen sp^2 methine groups, as well as for one sp^3 and seven sp^2 quaternary carbons. Furthermore, the signals of four carbonyl carbons, one of them belonging to an isolated keto group (δ_{C-21} 211.2), were present. Five proton signals missing in the ^{13}C -HSQC spectrum were assigned to NH groups. The remaining two oxygen and two hydrogen atoms

Fig. 1. Structure of aspochalasin Z (1).




were attributed to two hydroxy groups bound to two of the sp^3 methine groups as indicated by their chemical shifts (δ_C 78.5 and δ_C 74.5).

Seven spin networks were deduced from TOCSY and DQF-COSY spectra as depicted in Fig. 2. The largest spin network extended from 2-H to 13-H and further included the isopropyl substituent at C-10 (22-H to 24-H₃) and the methyl group at C-14 (25-H₃). HMBC connectivities (Fig. 2) enabled the assignment of the quaternary sp^2 carbons C-6 and C-14, and served to define the vicinal positions of the central bridgehead carbon C-9, the amide carbonyl carbon C-1, and the keto carbon C-21. Observation of HMBC cross peaks to C-14 and C-21 from protons of the second spin system (15-H₂ to 20-H₂ and 26-H) established the aspochalasin moiety of the molecule as 19-amino-17,18-dihydroxy-10-isopropyl-14-methyl[11]cytochalasa-6Z,13E-diene-1,21-dione³.

Starting from the indole nitrogen proton 42-H displaying the typical downfield shift (δ_H 11.06) the didehydrotryptamine moiety was secured fusing its three spin systems by HMBC connectivities. The (38E) configuration was deduced from the vicinal coupling constant of $^3J_{38,39}=15$ Hz. The amino acids anthranilic acid and alanine were derived from their spin systems and HMBC connectivities, and the tripeptidic sequence was determined from HMBC cross peaks of the amide protons (37-H to C-36 and 34-H to C-33). Finally, the connection between the aspochalasin and the tripeptidic part of the molecule became evident through HMBC cross peaks from 19-H to C-27 and from 26-H to C-28 and C-32.

Analysis of the NMR data of **3** (Table 1) revealed its planar structure to be identical to that of **2** (Fig. 3), while the planar structures of **4** and **5** (Fig. 3) were elucidated as the 17-deoxy and the 17,18-dideoxy analogs of **2** or **3**, respectively. Chiral amino acid analyses of **2**~**5** revealed

Fig. 2. Spin networks (bold lines) deduced from DQF-COSY and TOCSY spectra and selected HMBC connectivities (arrows) defining quaternary carbons and the linkage between the aspochalasin and tripeptidic moieties for aspochalamins A and B (**2**, **3**).




the L configuration of the alanine moiety for each compound. The structures of **2**~**5** were thus elucidated to consist of an aspochalasin moiety varying among the metabolites in the presence and number of hydroxy groups and/or the stereochemistry and of the tripeptidic moiety anthranoyl-L-alanine-E-didehydrotryptamide. Emphasizing the amino group at position C-19 connecting the aspochalasin with the tripeptidic part metabolites **2**~**5** were named aspochalamins A~D.

Discussion

The aspochalasin family^{3~11} is a subgroup of the cytochalasins characterised by a 2-methyl-propyl group at the C-3 position of the perhydroisindol-1-moiety and an 11-membered carbocyclic or 12-membered macrocyclic lactone ring connecting the C-8 and C-9 positions. With the

Fig. 3. Structures of aspochalamins A (2), B (3), C (4), and D (5).



Aspochalamin A (2):	$R^1=R^2=OH$
Aspochalamin B (3):	$R^1=R^2=OH$
Aspochalamin C (4):	$R^1=H, R^2=OH$
Aspochalamin D (5):	$R^1=R^2=H$

exception of the C-16 substitution in phomacins A~C¹⁰, variations among aspochalasins occur only at positions C-17 to C-20. The substitution pattern of a 17,18-diol moiety as in aspochalamins A (2) and B (3) is already known from the 17-epimers aspochalasins C and D^{5,13}, and from aspochalasin I¹⁰. The relative configurations of these aspochalasin analogs were determined by X-ray¹² and NOE and coupling constant analyses^{10,13}. Aspochalamin C (4) resembles TMC-169⁸ and aspochalamin J¹⁰ in possessing a single hydroxy group at position C-18, while the absence of oxygen functionalities at positions C-17 to C-20 links aspochalamin D (5) with aspochalasin Z (1).

It is generally assumed that the stereochemistry of the cyclohexene and isoindole moieties is the same in all cytochalasins¹⁴. Therefore, we depicted the stereochemistry of 1~5 as shown in Figs. 1 and 3.

However, apart from the determination of the absolute configuration of C-35 (L-alanine moiety), stereochemical studies of 1~5 have not been conducted yet. Of particular interest will be the stereochemistry at positions C-17 to C-19 in aspochalamins A~D.

What sets aspochalamins apart from aspochalasins and other cytochalasan compounds is the tripeptidic substitution. Tripeptidic substances containing a dihydrotryptamide functionality have been reported as fungal metabolites^{15~17}. Penidiamide¹⁷, which is anthranoyl-glycine-*E*-dihydrotryptamide, is closely related to the tripeptidic moiety of the aspochalamins. The aspochalamins constitute a unique combination of structural elements known from fungal metabolites.

Experimental

NMR Spectroscopy

NMR spectra of aspochalasin Z (1) were recorded on a Varian Inova 500 spectrometer at 500 MHz (¹H) and 125 MHz (¹³C) in DMSO-*d*₆ at 308 K.

NMR experiments on aspochalamins A~D (2~5) were carried out on a Bruker AMX2-600 spectrometer at 600 MHz (¹H) and 150 MHz (¹³C) in DMSO-*d*₆ at 305 K (2, 3) and in CDCl₃ at 298 K (4, 5). Chemical shifts are given in ppm relative to the solvent signal at δ_H 2.50 and δ_C 39.5 (DMSO-*d*₆) or relative from TMS as an internal standard.

Mass Spectrometry

ESI-mass spectra of 1 were acquired on a Finnigan LQC mass spectrometer.

High resolution electrospray ionisation Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICR-MS)¹⁸ of aspochalamins A~D (2~5) was performed on a passively shielded 4.7 Tesla ApexTM II ESI/MALDI-FTICR mass spectrometer (Bruker Daltonik, Bremen, Germany). The mass spectrometry software XMASS version 5.0.10 (Bruker Daltonik) running on a Silicon Graphics O2 Workstation was used for data acquisition and processing. In general 512k data points were acquired. An internal four point calibration was performed. Mass calculation was done by using the standard elemental mass compilation of AUDI & WAPSTRA¹⁹. Direct infusion experiments with ESI (Analytica of Branford) were performed in the positive mode with a grounded capillary sprayer needle mounted 60° off-axis. No supporting nebulizer gas was used applying a flow rate of 1 μ l/minute.

Chiral Amino Acid Analysis

Samples (approx. 50 nmol) were hydrolysed in 6 N HCl at 110°C for 24 hours. The free amino acids were derivatised to their *N*-trifluoroacetylated ethyl esters²⁰⁾ and analysed on a GC-mass spectrometer (MSD 6890/5973, Agilent, Waldbronn, Germany) using a fused silica capillary coated with Lipodex E - PS 255 (30 : 70).

References

- 1) FIEDLER, H-P: Biosynthetic capacities of actinomycetes. 1. Screening for secondary metabolites by HPLC and UV-visible absorbance spectral libraries. *Nat. Prod. Lett.* 2: 119~128, 1993
- 2) GEBHARDT, K.; J. SCHIMANA, A. HÖLTZEL, K. DETTNER, S. DRAEGER, W. BEIL, J. RHEINHEIMER & H.-P. FIEDLER: Aspochalamins A~D and aspochalasin Z produced by the endosymbiotic fungus *Aspergillus niveus* LU 9575. I. Taxonomy, fermentation, isolation and biological activities. *J. Antibiotics* 57: 707~714
- 3) BINDER, M.; CH. TAMM, W. B. TURNER & H. MINATO: Nomenclature of a class of biologically active mold metabolites. Cytochalasins, phomins, and zygosporins. *J. Chem. Soc. Perkin Trans. 1* 1973: 1146~1147, 1973
- 4) HEBERLE, W.; W. LOEFFLER & W. A. KONIG: Stoffwechselprodukte von Mikroorganismen, 136. Mitteilung. Asposterol, ein Antibiotikum aus *Aspergillus microcysticus*. *Arch. Microbiol.* 100: 73~95, 1974
- 5) KELLER-SCHIERLEIN, W. & E. KUPFER: Stoffwechselprodukte von Mikroorganismen, 157. Mitteilung. Über die Aspochalasine A, B, C und D. *Helv. Chim. Acta* 62: 1501~1524, 1979
- 6) NARUSE, N.; H. YAMAMOTO, S. MURATA, Y. SAWADA, Y. FUKAGAWA & T. OKI: Aspochalasin E, a new antibiotic isolated from a fungus. *J. Antibiotics* 46: 679~681, 1993
- 7) FANG, F.; H. UI, K. SHIOMI, R. MASUMA, Y. YAMAGUCHI, C. G. ZHANG, X. W. ZHANG, Y. TANAKA & S. ŌMURA: Two new components of the aspochalasins produced by *Aspergillus* sp. *J. Antibiotics* 50: 919~925, 1997
- 8) KOHNO, J.; N. NONAKA, M. NISHIO, T. OHNUKI, K. KAWANO, T. OKUDA & S. KOMATSUBARA: TMC-169, a new antibiotic of the aspochalasin group produced by *Aspergillus flavipes*. *J. Antibiotics* 52: 575~577, 1999
- 9) TOMIKAWA, T.; K. SHIN-YA, H. SETO, N. OKUSA, T. KAJIURA & Y. HAYAKAWA: Structure of aspochalasin H, a new member of the aspochalasin family. *J. Antibiotics* 55: 666~668, 2002
- 10) ZHOU, G.-X.; E. M. K. WIJERATNE, D. BIGELOW, L. S. PIERSON III, H. D. VANETTEN & A. A. L. GUNATILAKA: Three new cytotoxic cytochalasans of *Aspergillus flavipes* from the rhizosphere of *Ericameria laricifolia* of the Sonoran Desert. *J. Nat. Prod.* 67: 328~332, 2004
- 11) ALVI, K. A.; B. NAIR, H. PU, R. URSINO, C. GALLO & U. MOCEK: Phomacins: three novel antitumor cytochalasan constituents produced by a *Phoma* sp. *J. Org. Chem.* 62: 2148~2151, 1997
- 12) NEUPERT-LAVES, K. & M. DOBLER: Stoffwechselprodukte von Mikroorganismen, 139. Mitteilung. Röntgenstrukturanalyse von Di-O-acetyl-aspochalasin C. *Helv. Chim. Acta* 65: 1426~1431, 1982
- 13) TOMIKAWA, T.; K. SHIN-YA, T. KINOSHITA, A. MIYAJIMA, H. SETO & Y. HAYAKAWA: Selective cytotoxicity and stereochemistry of aspochalasin D. *J. Antibiotics* 54: 379~381, 2001
- 14) BINDER, M. & CH. TAMM: Die Cytochalasane, eine neue Klasse biologisch aktiver Metabolite von Mikroorganismen. *Angew. Chem.* 85: 369~420, 1973
- 15) KAGAMIZONO, T.; N. SAKAI, K. ARAI, K. KOBINATA & H. OSADA: Terpeptin, a novel mammalian cell cycle inhibitor, produced by *Aspergillus terreus* 95F-1. *Tetrahedron Lett.* 38: 1223~1226, 1997
- 16) TOSKE, S. G.; P. R. JENSEN, C. A. KAUFFMAN & W. FENICAL: Aspergillamides A and B: modified cytotoxic tripeptides produced by a marine fungus of the genus *Aspergillus*. *Tetrahedron* 54: 13459~13466, 1998
- 17) WITTER, L.; T. ANKE & O. STERNER: A new inhibitor of synovial phospholipase A2 from fermentations of *Penicillium* sp. 62~92. *Z. Naturforsch., C: Biosci.* 53: 60~64, 1998
- 18) MARSHALL, A. G.; C. L. HENDRICKSON & G. S. JACKSON: Fourier transform ion cyclotron resonance mass spectrometry: a primer. *Mass Spectrom. Rev.* 17: 1~35, 1998
- 19) AUDI, G. & A. H. WAPSTRA: Update to the atomic mass evaluation. *Nucl. Phys. A* 595: 409~480, 1995
- 20) SCHURIG, V.; M. JUZA, M. PRESCHER, G. J. NICHOLSON & E. BAYER: Gas-chromatographic enantiomer separation of proteinogenic amino acid derivatives: comparison of Chirasil-Val and Chirasil- γ -Dex used as chiral stationary phases. *Enantiomer* 4: 297~303, 1999